Abstract 93P
Background
Malnutrition, a problem often missed among patients with colorectal cancer, can result in decreased survival. However, its prevalence has not yet been evaluated in our institution. This study aimed to determine the nutritional status among patients with colorectal cancer at the Philippine General Hospital and identify predictors for malnutrition.
Methods
A cross-sectional study was conducted among all patients with colorectal cancer seen at the Philippine General Hospital Cancer Institute between December 2019 to February 2020. Anthropometric measurements were taken and nutritional status was evaluated using the Subjective Global Assessment tool. Descriptive statistics, ANOVA and logistic regression were employed to analyze the data.
Results
A total of 292 participants were included in the study with a high prevalence of cachexia (25.34%), sarcopenia (31.16%), and malnutrition (76.37%). Notably, only 17% of patients were referred by oncologists to the dietary service. The presence of liver metastasis and multiple sites of metastases were associated with increasing degree of malnutrition across SGA B and C (p = 0.05). Additionally, more patients with lung and peritoneal metastases were classified as malnourished (p = 0.05). Patients who did not receive chemotherapy, radiation, or surgery were more likely to be malnourished compared to those who previously received or were currently receiving treatment (chemotherapy: p < 0.01; radiation: p = 0.04; surgery: p < 0.01). Furthermore, patients with stage III disease had a higher odds for malnutrition (OR: 6.22, p < 0.01) compared to those with stage I and II disease, while patients who received or were currently receiving chemotherapy were less likely to have malnutrition than those who did not (OR: 0.35, p < 0.01).
Conclusions
Due to the high prevalence of malnutrition among patients with colorectal cancer, routine nutritional evaluation is important. Moreover, the high prevalence of cachexia and sarcopenia warrants early and adequate nutritional intervention. Thus, a hospital-wide program focusing on early nutritional assessment is recommended for implementation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Philippine General Hospital.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
95P - Prognosis of Japanese patients with detailed RAS/BRAF mutant colorectal cancer
Presenter: Tatsuki Ikoma
Session: e-Poster Display Session
96P - Early-onset colorectal cancer prognosis, conflict resolution, review of literature and meta-analysis
Presenter: Ereny Poles
Session: e-Poster Display Session
97P - A population-based study to assess the associations of rural residence and low socioeconomic status (SES) with cardiovascular disease (CVD) in patients with colorectal cancer (CRC)
Presenter: Atul Batra
Session: e-Poster Display Session
98P - Operational challenges of an Asian Pacific (APAC) academic oncology clinical trial
Presenter: Daphne Day
Session: e-Poster Display Session
99P - Development of a qRT-PCR-based diagnostic test to identify colorectal cancer patients with recurrent R-Spondin gene fusions
Presenter: Veronica Diermayr
Session: e-Poster Display Session
100P - Individualized treatment of advanced digestive system tumour guided by PDTX mouse model: A multicenter trial
Presenter: yuan cheng
Session: e-Poster Display Session
101P - HIF1-α depletion overcomes resistance to oxaliplatin in colorectal cancer via ERK signalling pathway
Presenter: Se Jun Park
Session: e-Poster Display Session
102P - Colorectal cancer organoids culture exploits new neoadjuvant therapy resistance mechanisms and therapeutic targets
Presenter: Yun Deng
Session: e-Poster Display Session
103P - Comprehensive genomic landscape in younger and older Chinese patients with colorectal cancer
Presenter: Huina Wang
Session: e-Poster Display Session
104P - Safety and efficacy of HLX04 versus reference bevacizumab in combination with XELOX or mFOLFOX6 as first-line treatment for metastatic colorectal cancer: A randomised, double-blind phase III study
Presenter: Shukui Qin
Session: e-Poster Display Session